10 likes | 83 Views
In 2017, the total prevalent population of Chronic Kidney Disease (CKD) was found to be 122,704,658 in the seven major markets. The prevalent population of Chronic Kidney Disease in the United States was 35,288,932 while Japan had 21,183,442 prevalent cases of CKD in 2017. <br><br>The market size of Chronic Kidney Disease (CKD) in the 7MM is estimated to be USD 16,897.5 Million by 2030. <br><br>Advances and future research, increasing prevalence of CKD, opportunities associated with CKD, and early detection & precision medicine are some of key factors expected to drive the CKD market forward in the coming years.<br><br>Some of the key players in the Chronic Kidney Disease (CKD) market includes GlaxoSmithKline, Akebia Therapeutics, Tricida Pharma, AstraZeneca, FibroGen, Astellas Pharma, Corvidia Therapeutics, Boehringer Ingelheim, Reata Pharmaceuticals and many others.<br><br>For more details visit: https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market<br><br>
E N D